The Ispor Scientific Presentations Database

ISPOR 20th Annual International Meeting
Philadelphia, PA, USA
May, 2015
PCN137
Cancer
Health Care Use & Policy Studies (HP)
Disease Management (DISM), Health Care Research (HCR)
METASTATIC MELANOMA PATIENT CHARACTERISTICS AS A DETERMENING FACTOR FOR BRAF GENE MUTATION TESTING AND TREATMENT IN CANADA – A RETROSPECTIVE COHORT STUDY
Djokic S1, Lapierre M2
1IMS Health, Ottawa, ON, Canada, 2IMS Health, Kirkland, QC, Canada
OBJECTIVES: To characterize patients and treatment approaches relative to BRAF gene mutation testing. METHODS: An analysis of patient characteristics, diagnostic and treatment including BRAF testing, age, co-morbidities, number of tumor sites, hospital vocation and type of therapy used was conducted using the information included in the IMS Brogan Enhanced Tumor Study database from October 2013 to September 2014. RESULTS: Out of 343 stage IV melanoma patients, 239 were tested for BRAF mutations. 57% (136 pts.) were BRAF positive, 36% (87 pts.) BRAF negative and for 7% (16 pts.) results were not reported. Patients who were tested for BRAF tended to be less than 50 years of age (46% vs. 16%, p<0.01), have none or only 1 co-morbidity (87% vs. 70%, p<0.01), have only 1 metastasis (34% vs. 45%, p<0.05), and treated in an academic facility (74% vs. 50%, p<0.01) compared to those who were not tested. BRAF negative patients were more often treated with ipilimumab compared to those who were not tested (42% vs. 10%, p<0.01). CONCLUSIONS: Patients characteristics emerged as an important factor for determining diagnostic and treatment protocols for metastatic melanoma patients in Canada. Younger patients and those with more favorable disease characteristics are more likely to be tested for BRAF mutations and treated with ipilimumab in those without BRAF mutation. BRAF testing appears to be more prevalent in academic centers than in community hospitals.